Home Physical Sciences Crystal structure of (E)-7-fluoro-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)methylene)-3,4-dihydronaphthalen-1(2H)-one, C21H22FN3O
Article Open Access

Crystal structure of (E)-7-fluoro-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)methylene)-3,4-dihydronaphthalen-1(2H)-one, C21H22FN3O

  • Yu Chen , Wen-Xin Zhu , Wen-Xuan Li , Yan Ren and Gui-Ge Hou ORCID logo EMAIL logo
Published/Copyright: July 28, 2025
Download Article (PDF)
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Zeitschrift für Kristallographie - New Crystal Structures
From the journal Zeitschrift für Kristallographie - New Crystal Structures Volume 240 Issue 5

Abstract

C21H22FN3O, monoclinic, P21/c (no. 14), a = 17.2795(3) Å, b = 6.1659(1) Å, c = 16.7198(3) Å, β = 90.596(1)°, V = 1781.29(5) Å3, Z = 4, Rgt(F) = 0.0408, wRref(F2) = 0.1122, T = 293 K.

CCDC no.: 2440890

The crystal structure is shown in the figure. Displacement ellipsoids are drawn at the 30 % probability level.

Table 1 contains the crystallographic data and the list of the atoms including atomic coordinates and displacement parameters can be found in the cif-file attached to this article.

Table 1:

Data collection and handling.

Crystal: Clear light yellow block
Size: 0.14 × 0.13 × 0.10 mm
Wavelength: CuKα radiation (1.54178 Å)
μ: 0.72 mm−1
Diffractometer, scan mode: Rigaku Synergy, ω scan
θmax, completeness: 74.9°, 99 %
N(hkl)measured, N(hkl)unique, Rint: 11071, 3489, 0.016
Criterion for Iobs, N(hkl)gt: Iobs > 2σ(Iobs), 3,297
N(param)refined: 236
Programs: Rigaku 1 , SHELX 2 , 3

1 Source of material

According to the synthesis method described in references, 4 , 5 , 6 N-methylpiperazine (16.05 g, 0.16 mol) and potassium carbonate (27.64 g, 0.20 mol) were weighed and added to a 250 mL round bottom reaction flask. N,N-dimethylformamide (15.0 mL) was used as the reaction solvent. The mixture was stirred at 353 K for about 4 h. 5-Fluorolinaldehyde (2.54 g, 0.02 mol) was added after 4 h and refluxed at 373 K to continue the reaction for about 5 h. The reaction progress is detected by Thin-Layer Chromatography (TLC, dichloromethane: methyl alcohol = 20:1, v:v). After the reaction system droped to room temperature, the precipitate was filtered and washed with dichloromethane to give a light yellow solid (22.0 mL). Spin evaporate the solvent and using dichloromethane: methyl alcohol (50:1, v:v) as the eluent to obtain the intermediate. 7-Fluoro-3,4-dihydronaphthalen-1(2H)-one (1.64 g, 0.01 mol) and intermediate (2.1 g, 0.01 mol) were reacted at 293 K for 7 h using methanol (25.0 mL) as the solvent and 25 % sodium hydroxide (20.0 mL) as the catalyst. After completion of the reaction, the precipitate was filtered and washed with 50 % methanol. 7 Finally, recrystallization gave yellow crystals of the title compound from dichloromethane and methanol solutions (1:1, v:v).

2 Experimental details

The H atoms were placed in idealized positions and treated as riding on their parent atoms, with d(C–H) = 0.96 Å (methyl), Uiso(H) = 1.5Ueq(C), and d(C–H) = 0.97 Å (methylene), Uiso(H) = 1.2Ueq(C), and d(C–H) = 0.93 Å (aromatic), Uiso(H) = 1.2Ueq(C).

3 Comment

3,4-Dihydronaphthalene-1(2H)-one derivatives are of interest because of their wide range of biological activities. 8 There is a large structural modification of space on its right side, and through skeleton assembly strategy, 3,4-dihydronaphthalene-1(2H)-one can be assembled with multiple active functional groups, which can endow it with various effects, such as anti rheumatic, anti skin disease, anti-tumor, and anti Alzheimer’s disease. 9 Pyridine or dihydropyridine modification is one of the most widely used heterocycles in the field of drug design. Their excellent therapeutic effects have expanded the scope of finding treatments for other diseases. 10 N-methylpiperazine, as another nitrogen-containing heterocyclic ring containing two N atoms, has been found to have excellent anti-inflammatory, antibacterial, and anti-tumor activities. 11 , 12 Therefore, we first spliced N-methylpiperazine and 5-fluoropicolinaldehyde, two nitrogen-containing heterocycles, into 5-(4-methylpiperazin-1-yl)picolinaldehyde through substitution reaction. 13 Secondly, the fluorine atom has a strong electronegativity, which can improve its lipophilicity and enhance its bioavailability. 14 So we used 7-fluoro-3,4-dihydronaphthalen-1(2H)-one and 5-(4-methylpiperazin-1-yl)picolinaldehyde for the Claisen–Schmidt reaction to obtain the title compound.

The single crystal structure analysis revealed that there is only one drug molecule in the asymmetric unit (cf. the figure), and the bond lengths and bond angles of the compound are within the normal range. 3,4-Dihydronaphthalene-1(2H)-one is the main active site of the title compound. 15 , 16 In this parent nucleus, the fluorine atom is connected to C(7) position, the bond length of C(7)–F(1) is 1.3585(16) Å. Introducing 5-(4-methylpiperazin-1-yl)picolinaldehyde at C(2) position can form an α,β-unsaturated ketone structure. The bond length of C(1)=O(1) is 1.2236(15) Å, and the bond length of C(2)=C(11) is 1.3439(17) Å. In addition, the twist angle of O(1)=C(1)–C(2)=C(11) is −17.37(17)°. Through the C(2)=C(11) double bond, the molecule derives a pyridine substituent, with a twist angle of −22.7(2)° for C(2)=C(11)–C(12)=N(1). The bond lengths of C(12)=N(1) is 1.3440(16) Å. The parent nucleus is not coplanar with the pyridine ring, and the dihedral angle is approximately 45.05(4)°. N-methylpiperazine is attached to C(15) position, and displays “chair” conformation. The twist angle of N(2)–C(17)–C(18)–N(3) and N(2)–C(20)–C(19)–N(3) are about 54.39(14)° and −53.52(13)°, respectively.

Corresponding author: Gui-Ge Hou, School of Pharmacy, Binzhou Medical University, Yantai, 264003, P.R. China, E-mail:

Funding source: Shandong Laboratory Program

Award Identifier / Grant number: SYS202205

Funding source: Shandong Provincial Natural Science Foundation

Award Identifier / Grant number: ZR2022MH159

Award Identifier / Grant number: ZR2023MH190

Funding source: Shandong Province Science and Technology-based Small and Medium-sized Enterprises Innovation Capacity Enhancement Project

Award Identifier / Grant number: 2023TSGC0870

  1. Research funding: This work was supported by Shandong Laboratory Program (No. SYS202205), Shandong Provincial Natural Science Foundation (Nos. ZR2022MH159 and ZR2023MH190) and Shandong Province Science and Technology-based Small and Medium-sized Enterprises Innovation Capacity Enhancement Project (No. 2023TSGC0870).

References

1. Rigaku OD. CrysAlisPRO; Rigaku Oxford Diffraction Ltd: Yarnton, Oxfordshire, England, 2017.Search in Google Scholar

2. Sheldrick, G. M. A Short History of Shelx. Acta Crystallogr. 2008, A64, 112–122. https://doi.org/10.1107/s0108767307043930.Search in Google Scholar PubMed

3. Sheldrick, G. M. Crystal Structure Refinement with Shelxl. Acta Crystallogr. 2015, C71, 3–8. https://doi.org/10.1107/s2053229614024218.Search in Google Scholar

4. Luo, H. L.; Li, W. X.; Bai, X. Y.; Meng, Q. G.; Hou, Y. Crystal Structure of (E)-7-Fluoro-2-(4-Morpholinobenzylidene)-3,4-Dihydronaphthalen-1(2H)-One, C21H20FNO2. Z. Kristallogr. N. Cryst. Struct. 2023, 238 (3), 495–497. https://doi.org/10.1515/ncrs-2023-0053.Search in Google Scholar

5. Chen, Y.; Wang, J. P.; Wang, M. D.; Yu, W. X.; Cui, Y. T.; Gao, H. X.; Hou, G. G.; Ren, Y. Crystal Structure of (E)-2-(4-(1H-Imidazol-1-yl)Benzylidene)-7-Fluoro-3,4-Dihydronaphthalen-1(2H)-One, C20H15FN2O. Z. Kristallogr. N. Cryst. Struct. 2025, 240 (1), 19–21. https://doi.org/10.1515/ncrs-2024-0294.Search in Google Scholar

6. Yuan, X. Q.; Zhao, L. H.; Zhang, J. J.; Hou, G. G. Crystal Structure of (E)-7-Methoxy-2-(4-Morpholinobenzylidene)-3,4-Dihydronaphthalen-1(2H)-One, C22H23NO3. Z. Kristallogr. N. Cryst. Struct. 2023, 238, 363–365. https://doi.org/10.1515/ncrs-2022-0578.Search in Google Scholar

7. Xia, D. L.; Wang, J. P.; Yu, W. X.; Wang, M. D.; Gao, H. X.; Cui, Y. T.; Hou, G. G. Crystal Structure of (E)-6,8-Dimethoxy-4-(4-Morpholinobenzylidene)-3,4-Dihydro-1-Benzoxepin-5(2H)-One, C23H25NO5. Z. Kristallogr. N. Cryst. Struct. 2024, 239 (6), 1133–1136. https://doi.org/10.1515/ncrs-2024-0329.Search in Google Scholar

8. Kirby, A. J.; Le, L. R.; Maharlouie, F.; Mason, P.; Nicholls, P. J.; Smith, H. J.; Simons, C. Inhibition of Retinoic Acid Metabolising Enzymes by 2-(4-Aminophenylmethyl)-6-Hydroxy-3,4-Dihydronaphthalen-1(2H)-One and Related Compounds. J. Enzyme Inhib. Med. Chem. 2003, 18 (1), 27–33. https://doi.org/10.1080/1475636021000049221.Search in Google Scholar PubMed

9. Li, W. X.; Yu, L.; Chi, J. B.; Wang, J. P.; Liu, Y. J.; Wang, C. H.; Zhang, M.; Hou, G. G. Discovery of Anti-inflammatory Agents from 3,4-Dihydronaphthalene-1(2H)-One Derivatives by Inhibiting NLRP3 Inflammasome Activation. Eur. J. Med. Chem. 2024, 268, 116284. https://doi.org/10.1016/j.ejmech.2024.116284.Search in Google Scholar PubMed

10. Ling, Y.; Hao, Z. Y.; Liang, D.; Zhang, C. L.; Liu, Y. F.; Wang, Y. The Expanding Role of Pyridine and Dihydropyridine Scaffolds in Drug Design. Drug Des. Devel. Ther. 2021, 15, 4289–4338. https://doi.org/10.2147/dddt.s329547.Search in Google Scholar

11. Girase, P. S.; Dhawan, S.; Kumar, V.; Shinde, S. R.; Palkar, M. B.; Karpoormath, R. An Appraisal of Anti-mycobacterial Activity with Structure-Activity Relationship of Piperazine and its Analogues: A Review. Eur. J. Med. Chem. 2021, 210, 112967. https://doi.org/10.1016/j.ejmech.2020.112967.Search in Google Scholar PubMed

12. Qi, Q. B.; Li, W. X.; Hou, G. G.; Li, C. B. Crystal Structure of (E)-7-Bromo-2-(4-(4-Methylpiperazin-1-yl)Benzylidene)-3,4-Dihydronaphthalen-1(2H)-One, C22H23BrN2O. Z. Kristallogr. N. Cryst. Struct. 2023, 238, 235–237. https://doi.org/10.1515/ncrs-2022-0590.Search in Google Scholar

13. Yu, L.; Wang, J. P.; Wang, M. D.; Yu, W. X.; Cui, Y. T.; Gao, H. X.; Liu, Y. J.; Hou, G. G. Crystal Structure of (E)-6-(4-Ethylpiperazin-1-yl)-2-(3-Fluorobenzylidene)-3,4-Dihydronaphthalen-1(E)-One, C23H25FN2O. Z. Kristallogr. N. Cryst. Struct. 2024, 239, 515–517. https://doi.org/10.1515/ncrs-2024-0066.Search in Google Scholar

14. Li, X. W.; Miao, Y. H.; Ding, Y. X.; Hou, G. G. Crystal Structure of 9-Fluoro-4-(6-Methoxypyridin-2-yl)-5,6-Dihydrobenzo [(h)]quinazolin-2-Amine, C18H15FN4O. Z. Kristallogr. N. Cryst. Struct. 2025, 240 (1), 37–39. https://doi.org/10.1515/ncrs-2024-0330.Search in Google Scholar

15. Zhang, X. F.; Luan, M. Z.; Yan, W. B.; Zhao, F. L.; Hou, Y.; Hou, G. G.; Meng, Q. G. Anti-neuroinflammatory Effects of Novel 5,6-Dihydrobenzo [h]quinazolin-2-Amine Derivatives in Lipopolysaccharide-Stimulated BV2 Microglial Cells. Eur. J. Med. Chem. 2022, 235, 114322. https://doi.org/10.1016/j.ejmech.2022.114322.Search in Google Scholar PubMed

16. Sun, Y.; Zhou, Y. Q.; Liu, Y. K.; Zhang, H. Q.; Hou, G. G.; Meng, Q. G.; Hou, Y. Potential Anti-neuroinflammatory NF-κB Inhibitors Based on 3,4-Dihydronaphthalen-1(2H)-One Derivatives. J. Enzym. Inhib. Med. Chem. 2020, 35, 1631–1640. https://doi.org/10.1080/14756366.2020.1804899.Search in Google Scholar PubMed PubMed Central

Received: 2025-06-03
Accepted: 2025-07-21
Published Online: 2025-07-28
Published in Print: 2025-10-27

© 2025 the author(s), published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.

Articles in the same Issue

  1. Frontmatter
  2. New Crystal Structures
  3. Crystal structure of (S)-N-(10-((2,2-dimethoxyethyl)amino)-1,2,3-trimethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl)acetamide, C25H32N2O7
  4. The crystal structure of 6,6′-difluoro-3,3′-dimethyl-5,5′-di(10H-phenoxazin-10-yl)- [1,1′-biphenyl]-2,2′-dicarbonitrile, C40H24F2N4O2
  5. Crystal structure of poly[(di-ethylenediamine-κ2N,N′)cadmium(II) tetradedocyloxidohexavanadate] (V4+/V5+ = 2/1), C4H16CdN4O14V6
  6. The crystal structure of poly[bis(dimethylformamide-κ1N)-(μ4-2′,3,3″,5′-tetrakis(trifluoromethyl)-[1,1′:4′,1″-terphenyl]-4,4″-dicarboxylato-κ4 O,O′: O″,O‴)dicadmium(II)], C27H15CdF12NO5
  7. Crystal structure of bis(μ2-ferrocenylcarboxylato-O,O′)-(μ3-oxido-κ3O:O:O)-bis(μ2-salicyladoximato-κ2N,O,O′)-(μ2-isopropoxo)-tris(isopropoxy-κ1O trititanium(IV)), C48H55N2O13Fe2Ti3
  8. Crystal structure of 3-(diethylamino)-7,9,11-trimethyl-8-phenyl-6H,13H-12λ4,13λ4-chromeno[3′,4′:4,5]pyrrolo[1,2-c]pyrrolo[2,1-f][1,3,2]diazaborinin-6-one, C28H26BF2N3O2
  9. The crystal structure of catena-poly[aqua-μ2-2-nitro-benzene-1,3-dicarboxylato-κ2O,O′)-(1,10-phenanthroline-κ2N,N′)-zinc(II)], C20H13N3O7Zn
  10. Crystal structure of poly[diaqua-{μ3-1-(3-carboxylatophenyl)-4-oxo-1,4-dihydropyridazine-3-carboxylato-κ4O,O′:O′′:O′′′′}manganese(II)] hydrate
  11. Crystal structure of N′-((1-hydroxycyclohexyl)(phenyl)methyl)-2-methoxybenzohydrazide methanol solvate, C22H28N2O4
  12. The cocrystal of caffeic acid — progesterone — water (1/2/1), C51H70O9
  13. Crystal structure of (((oxido(quinolin-6-yl)methoxy)triphenyl-λ5-stibanyl)oxy)(quinolin-7-yl)methanolate
  14. Crystal structure of [(E)-6′-(diethylamino)-2-(2-(((E)-pyren-1-ylmethylene)amino)ethyl)-4′-(2-((E)-1,3,3-trimethylindolin-2-ylidene)ethylidene)-1′,2′,3′,4′-tetrahydrospiro[isoindoline-1,9′-xanthen]-3-one]-methanol, solvate C57H56N4O3
  15. The crystal structure of 1-(acridin-9-yl)pyrrolidine-2,5-dione, C17H22N2O2
  16. Crystal structure of N-(4-acetylphenyl)-2-(6-methoxynaphthalen-2-yl)propanamide, C22H21NO3
  17. The crystal structure of 5,10,15,20-tetrakis(4-(1H-1,2,4-triazol-1-yl)phenyl)porphyrin, C52H34N16
  18. Crystal structure of hexacarbonyl-μ2-[phenylmethanedithiolato-κ4S:S,S′:S′]diiron (Fe–Fe) C13H6Fe2O6S2
  19. Crystal structure of diiodo-bis(1-((2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-1H-benzo[d][1,2,3]triazole-κ1N)cadmium(II), C34H34CdI2N10
  20. Crystal structure of (E)-(3-(3-bromophenyl)acryloyl)ferrocene, C19H15BrFeO
  21. Crystal structure of catena-poly(μ2-6-chloropyridine-2-carboxylato-κ3N,O:O′)(6-chloropyridine-2-carboxylato-κ2O,N)copper(II), C12H6Cl2N2O4Cu
  22. Crystal structure of poly[diaqua-μ 3-(5-(3,5-dicarboxy-2,4,6-trimethylbenzyl)-2,4,6-trimethylisophthalato)-κ 6O,O′:O″,O‴:O‴′,O‴″) terbium(III)-monohydrate], C23H28TbO12
  23. Crystal structure of (E)-2-(((5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene)amino)-3′,6′-dihydroxyspiro[isoindoline-1,9′-xanthen]-3-one – ethanol (1/2), C35H33ClN4O6
  24. The crystal structure of 3-(5-amino-3-phenylisoxazol-4-yl)-4-chloro-3-hydroxyindolin-2-one, C17H12ClN3O3
  25. The crystal structure of dimethylammonium 4-[2-(4-fluorophenyl)-4, 5-diphenyl-1H-imidazol-1-yl]benzenesulfonate, C29H26FN3O3S
  26. Crystal structure of (R)-2-ammonio-3-((5-carboxypentyl)thio)propanoate
  27. Crystal structure of 4-cyclohexyl-5-(thiophen-2-yl)-2,4-dihydro-3H-1,2,4-triazole-3-thione, C12H15N3S2
  28. The crystal structure of 4,6-bis(dimethylamino)-2-fluoroisophthalonitrile, C12H13FN4
  29. Hydrogen bonding in the crystal structure of nicotin-1,1′-dium tetrabromidomanganate(II)
  30. The crystal structure of bis(2-bromobenzyl)(2-((2-oxybenzylidene)amino)-4-methylpentanoato-κ3N, O,O′)tin(IV), C27H27Br2NO3Sn
  31. Crystal structure of (E)-(3-(p-tolyl)acryloyl)ferrocene, C20H18FeO
  32. Crystal structure of (E)-7-fluoro-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)methylene)-3,4-dihydronaphthalen-1(2H)-one, C21H22FN3O
  33. Crystal structure of (E)-7-methoxy-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)methylene)-3,4-dihydronaphthalen-1(2H)-one, C22H25N3O2
  34. The crystal structure of poly(bis(μ2-1,3,5-tri(1H-imidazol-1-yl)benzene-κ2N:N′)-(μ2-2,3,5,6-tetrafluoroterephthalato-κ2O:O′)-manganese(II), C38H24F4N12O4Mn
  35. Crystal structure of (3,4-dimethoxybenzyl)triphenylphosphonium bromide ethanol solvate, C29H32BrO3P
  36. Crystal structure of tetraethylammonium hydrogencarbonate – (diaminomethylene)thiourea – water (2/1/3)
  37. Crystal structure of N, N-Dimethyl-N′-tosylformimidamide, C10H14N2O2S
  38. The crystal structure of ethyl 2-methyl-5-oxo-4-(2-methoxyphenyl)-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate, C20H23N2O4
  39. Crystal structure of bis(μ2-1,5-bis[(E)-1-(2-hydroxyphenyl)ethylidene] thiocarbonohydrazide)-bis(dimethylformamide)-dizinc(II) dimethylformamide solvate, C40H46N10O6S2Zn2⋅C3H7NO
  40. Crystal structure of azido-κ1N{hydridotris(3-tert-butyl-5-methylpyrazol-1-yl)borato-κ3N,N′,N″}copper(II), C24H40BCuN9
  41. The crystal structure of fac-tricarbonyl(1,10-phenanthroline-κ2N,N′)-(azido-κ1N)rhenium(I), C15H8N5O3Re
  42. Crystal structure of 4-((triphenylphosphonio)methyl)pyridin-1-ium tetrachloridozincate(II), C24H22Cl4NPZn
https://doi.org/10.1515/ncrs-2025-0256
Creative Commons
BY 4.0

Articles in the same Issue

  1. Frontmatter
  2. New Crystal Structures
  3. Crystal structure of (S)-N-(10-((2,2-dimethoxyethyl)amino)-1,2,3-trimethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl)acetamide, C25H32N2O7
  4. The crystal structure of 6,6′-difluoro-3,3′-dimethyl-5,5′-di(10H-phenoxazin-10-yl)- [1,1′-biphenyl]-2,2′-dicarbonitrile, C40H24F2N4O2
  5. Crystal structure of poly[(di-ethylenediamine-κ2N,N′)cadmium(II) tetradedocyloxidohexavanadate] (V4+/V5+ = 2/1), C4H16CdN4O14V6
  6. The crystal structure of poly[bis(dimethylformamide-κ1N)-(μ4-2′,3,3″,5′-tetrakis(trifluoromethyl)-[1,1′:4′,1″-terphenyl]-4,4″-dicarboxylato-κ4 O,O′: O″,O‴)dicadmium(II)], C27H15CdF12NO5
  7. Crystal structure of bis(μ2-ferrocenylcarboxylato-O,O′)-(μ3-oxido-κ3O:O:O)-bis(μ2-salicyladoximato-κ2N,O,O′)-(μ2-isopropoxo)-tris(isopropoxy-κ1O trititanium(IV)), C48H55N2O13Fe2Ti3
  8. Crystal structure of 3-(diethylamino)-7,9,11-trimethyl-8-phenyl-6H,13H-12λ4,13λ4-chromeno[3′,4′:4,5]pyrrolo[1,2-c]pyrrolo[2,1-f][1,3,2]diazaborinin-6-one, C28H26BF2N3O2
  9. The crystal structure of catena-poly[aqua-μ2-2-nitro-benzene-1,3-dicarboxylato-κ2O,O′)-(1,10-phenanthroline-κ2N,N′)-zinc(II)], C20H13N3O7Zn
  10. Crystal structure of poly[diaqua-{μ3-1-(3-carboxylatophenyl)-4-oxo-1,4-dihydropyridazine-3-carboxylato-κ4O,O′:O′′:O′′′′}manganese(II)] hydrate
  11. Crystal structure of N′-((1-hydroxycyclohexyl)(phenyl)methyl)-2-methoxybenzohydrazide methanol solvate, C22H28N2O4
  12. The cocrystal of caffeic acid — progesterone — water (1/2/1), C51H70O9
  13. Crystal structure of (((oxido(quinolin-6-yl)methoxy)triphenyl-λ5-stibanyl)oxy)(quinolin-7-yl)methanolate
  14. Crystal structure of [(E)-6′-(diethylamino)-2-(2-(((E)-pyren-1-ylmethylene)amino)ethyl)-4′-(2-((E)-1,3,3-trimethylindolin-2-ylidene)ethylidene)-1′,2′,3′,4′-tetrahydrospiro[isoindoline-1,9′-xanthen]-3-one]-methanol, solvate C57H56N4O3
  15. The crystal structure of 1-(acridin-9-yl)pyrrolidine-2,5-dione, C17H22N2O2
  16. Crystal structure of N-(4-acetylphenyl)-2-(6-methoxynaphthalen-2-yl)propanamide, C22H21NO3
  17. The crystal structure of 5,10,15,20-tetrakis(4-(1H-1,2,4-triazol-1-yl)phenyl)porphyrin, C52H34N16
  18. Crystal structure of hexacarbonyl-μ2-[phenylmethanedithiolato-κ4S:S,S′:S′]diiron (Fe–Fe) C13H6Fe2O6S2
  19. Crystal structure of diiodo-bis(1-((2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-1H-benzo[d][1,2,3]triazole-κ1N)cadmium(II), C34H34CdI2N10
  20. Crystal structure of (E)-(3-(3-bromophenyl)acryloyl)ferrocene, C19H15BrFeO
  21. Crystal structure of catena-poly(μ2-6-chloropyridine-2-carboxylato-κ3N,O:O′)(6-chloropyridine-2-carboxylato-κ2O,N)copper(II), C12H6Cl2N2O4Cu
  22. Crystal structure of poly[diaqua-μ 3-(5-(3,5-dicarboxy-2,4,6-trimethylbenzyl)-2,4,6-trimethylisophthalato)-κ 6O,O′:O″,O‴:O‴′,O‴″) terbium(III)-monohydrate], C23H28TbO12
  23. Crystal structure of (E)-2-(((5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene)amino)-3′,6′-dihydroxyspiro[isoindoline-1,9′-xanthen]-3-one – ethanol (1/2), C35H33ClN4O6
  24. The crystal structure of 3-(5-amino-3-phenylisoxazol-4-yl)-4-chloro-3-hydroxyindolin-2-one, C17H12ClN3O3
  25. The crystal structure of dimethylammonium 4-[2-(4-fluorophenyl)-4, 5-diphenyl-1H-imidazol-1-yl]benzenesulfonate, C29H26FN3O3S
  26. Crystal structure of (R)-2-ammonio-3-((5-carboxypentyl)thio)propanoate
  27. Crystal structure of 4-cyclohexyl-5-(thiophen-2-yl)-2,4-dihydro-3H-1,2,4-triazole-3-thione, C12H15N3S2
  28. The crystal structure of 4,6-bis(dimethylamino)-2-fluoroisophthalonitrile, C12H13FN4
  29. Hydrogen bonding in the crystal structure of nicotin-1,1′-dium tetrabromidomanganate(II)
  30. The crystal structure of bis(2-bromobenzyl)(2-((2-oxybenzylidene)amino)-4-methylpentanoato-κ3N, O,O′)tin(IV), C27H27Br2NO3Sn
  31. Crystal structure of (E)-(3-(p-tolyl)acryloyl)ferrocene, C20H18FeO
  32. Crystal structure of (E)-7-fluoro-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)methylene)-3,4-dihydronaphthalen-1(2H)-one, C21H22FN3O
  33. Crystal structure of (E)-7-methoxy-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)methylene)-3,4-dihydronaphthalen-1(2H)-one, C22H25N3O2
  34. The crystal structure of poly(bis(μ2-1,3,5-tri(1H-imidazol-1-yl)benzene-κ2N:N′)-(μ2-2,3,5,6-tetrafluoroterephthalato-κ2O:O′)-manganese(II), C38H24F4N12O4Mn
  35. Crystal structure of (3,4-dimethoxybenzyl)triphenylphosphonium bromide ethanol solvate, C29H32BrO3P
  36. Crystal structure of tetraethylammonium hydrogencarbonate – (diaminomethylene)thiourea – water (2/1/3)
  37. Crystal structure of N, N-Dimethyl-N′-tosylformimidamide, C10H14N2O2S
  38. The crystal structure of ethyl 2-methyl-5-oxo-4-(2-methoxyphenyl)-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate, C20H23N2O4
  39. Crystal structure of bis(μ2-1,5-bis[(E)-1-(2-hydroxyphenyl)ethylidene] thiocarbonohydrazide)-bis(dimethylformamide)-dizinc(II) dimethylformamide solvate, C40H46N10O6S2Zn2⋅C3H7NO
  40. Crystal structure of azido-κ1N{hydridotris(3-tert-butyl-5-methylpyrazol-1-yl)borato-κ3N,N′,N″}copper(II), C24H40BCuN9
  41. The crystal structure of fac-tricarbonyl(1,10-phenanthroline-κ2N,N′)-(azido-κ1N)rhenium(I), C15H8N5O3Re
  42. Crystal structure of 4-((triphenylphosphonio)methyl)pyridin-1-ium tetrachloridozincate(II), C24H22Cl4NPZn
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 26.12.2025 from https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2025-0256/html
Scroll to top button